Independent
Tenure on this board
12.6 yrs
Also a director at
Iqvia Holdings Inc (IQV)
Meeting calendar
RMD · Annual meeting · Wednesday, November 19, 2025
Resmed Inc
11 nominees · 5 ballot items.
Five proposals are being voted on: Proposal 1 Election of eleven directors; Proposal 2 Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026; Proposal 3 Advisory vote to approve named executive officer compensation; Proposal 4 Approval of the amendment and restatement of the ResMed Inc. 2009 Incentive Award Plan, including increase of reserved shares and elimination of fixed term; Proposal 5 Approval of the amendment and restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan, including increase of reserved shares and elimination of fixed term.
Market cap
$29.2B
1Y TSR
-22.7%
Board grade
C
Record date
Sep 23, 2025
Filing
DEF 14A
Meeting concluded · Nov 19, 2025
Follow how the vote landed and what changed on Resmed Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot5
- 1
Election of Directors
ManagementBoard: FORElection of eleven director nominees to serve on the Board for the coming year.
- 2
Ratification of Selection of KPMG LLP as Our Independent Registered Public Accounting Firm for Fiscal Year Ending June 30, 2026
ManagementBoard: FORRatification of the appointment of KPMG LLP as ResMed's independent registered public accounting firm for the fiscal year ending June 30, 2026.
- 3
Advisory Vote to Approve Named Executive Officer Compensation
ManagementBoard: FORAdvisory vote to approve the compensation of ResMed's named executive officers (say-on-pay).
- 4
Approval of the Amendment and Restatement of the ResMed Inc. 2009 Incentive Award Plan, Including Increase of Reserved Shares and Elimination of Fixed Term
ManagementBoard: FORAmend and restate the 2009 Incentive Award Plan to increase the number of reserved shares and eliminate the plan's fixed term.
- 5
Approval of the Amendment and Restatement of the ResMed Inc. 2018 Employee Stock Purchase Plan, Including Increase of Reserved Shares and Elimination of Fixed Term
ManagementBoard: FORAmend and restate the 2018 Employee Stock Purchase Plan to increase the number of reserved shares and eliminate the fixed term.
Director elections
Nominees on the ballot11
Independent
Tenure on this board
7.1 yrs
Independent
Tenure on this board
1.9 yrs
Independent
Tenure on this board
8.6 yrs
Also a director at
Outset Medical Inc (OM)EBRCZ
Not independent
Tenure on this board
13.3 yrs
Also a director at
Zimmer Biomet Holdings Inc (ZBH)
Not independent
Tenure on this board
37.1 yrs
Also a director at
Arcturus Therapeutics Holdings Inc (ARCT)
Independent
Tenure on this board
7.6 yrs
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
0.9 yrs
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
21.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.5% | 9,466,416 | $2.1B |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.4% | 7,863,922 | $1.8B |
| 3 | STATE STREET CORP | 4.6% | 6,643,168 | $1.5B |
| 4 | BlackRock, Inc. | 3.9% | 5,655,389 | $1.3B |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 3,887,748 | $869M |
| 6 | Bank of New York Mellon Corp | 2.2% | 3,139,259 | $705M |
| 7 | BlackRock, Inc. | 2.0% | 2,959,347 | $664M |
| 8 | FIRST TRUST ADVISORS LP | 1.1% | 1,536,343 | $345M |
| 9 | Swedbank AB | 0.9% | 1,350,234 | $303M |
| 10 | Invesco Ltd. | 0.8% | 1,224,093 | $275M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Resmed Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Steris PLCSTE
Annual meeting·Jul 31, 2026·$20.6B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Catalyst Pharmaceuticals IncCPRX
Special meeting·Jul 8, 2026·$3.8B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Reference
Frequently asked questions
- When is the Resmed Inc 2025 annual meeting?
- Resmed Inc (RMD) holds its 2025 annual shareholder meeting on Wednesday, November 19, 2025.
- What is the record date for the Resmed Inc 2025 meeting?
- The record date for the Resmed Inc 2025 meeting is Tuesday, September 23, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Resmed Inc's 2025 meeting?
- The board is presenting 11 director nominees at the Resmed Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Resmed Inc 2025 meeting?
- Shareholders will vote on 5 proposals at the Resmed Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.